EMU065521
MISSION® esiRNA
targeting mouse Nfatc2
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
NACRES:
NA.51
UNSPSC Code:
41105324
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarledescription
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
GAACAACATGAGAGCCACCATCGACTGTGCAGGCATCCTGAAGCTCCGAAACGCTGACATCGAGCTGCGGAAGGGCGAGACGGACATCGGCAGGAAGAACACGCGTGTGCGCCTGGTGTTCCGCGTGCACGTCCCAGAGCCCAGTGGGCGCATCGTCTCCCTGCAGGCTGCGTCCAACCCCATCGAGTGCTCTCAGCGCTCTGCCCACGAGCTGCCCATGGTGGAGAGACAAGACATGGACAGCTGCCTGGTCTACGGGGGCCAGCAGATGATCCTCACGGGCCAGAACTTCACAGCGGAGTCCAAGGTTGTGTTCATGGAGAAGACTACAGATGGGCAGCAGATTTGGGAGATGGAAGCTACGGTGGATAAAGACAAGAGCCAGCCTAACATGCTTTTTGTTGAGATCCCCGA
Ensembl | mouse accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
mouse ... NFATC2(18019), Nfatc2(18019)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Clase de almacenamiento
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Christina Springstead Scanlon et al.
Nature communications, 6, 6885-6885 (2015-04-29)
Perineural invasion (PNI) is an indicator of poor survival in multiple cancers. Unfortunately, there is no targeted treatment for PNI since the molecular mechanisms are largely unknown. PNI is an active process, suggesting that cancer cells communicate with nerves. However